| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$8,894 |
425 Ruling - Communication
|
27 Feb 2025 9:02AM |
$16.170 |
$14.150 |
fallen by
12.49%
|
|
| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$8,894 |
425 Ruling - Communication
|
27 Feb 2025 9:02AM |
$16.170 |
$14.150 |
fallen by
12.49%
|
|
| Rhythm Biosciences Limited (RHY) ORDINARY FULLY PAID |
Health Care |
$17 |
Investor Webinar
|
27 Feb 2025 9:01AM |
$0.094 |
$0.059 |
fallen by
37.23%
|
|
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$558 |
Corporate Governance Statement
|
27 Feb 2025 9:01AM |
$1.470 |
$1.395 |
fallen by
5.10%
|
|
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,294 |
Ryoncil Pricing Set and Available This Quarter
|
27 Feb 2025 9:01AM |
$2.460 |
$1.795 |
fallen by
27.03%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Ryoncil® will be available shortly for pediatric SR-aGvHD patients.
- The product has shown long-term survival benefits in high-risk patients.
- Ryoncil® is priced at $194,000 per infusion.
- Mesoblast is implementing financial assistance programs to ensure patient access.
- The company is collaborating with major transplant centers for distribution.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thorney Technologies Ltd (TEK) ORDINARY FULLY PAID |
Financials |
$38 |
Update - Notification of buy-back - TEK
|
27 Feb 2025 9:00AM |
$0.130 |
$0.100 |
fallen by
23.08%
|
|
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$536 |
Update - Notification of buy-back - ACL
|
27 Feb 2025 9:00AM |
$3.270 |
$2.730 |
fallen by
16.51%
|
|
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$818 |
Update - Notification of buy-back - DJW
|
27 Feb 2025 9:00AM |
$3.090 |
$3.110 |
risen by
0.65%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$112 |
Imugene Granted India Patent for Oncolytic Virotherapy CF33
|
27 Feb 2025 8:59AM |
$0.036 |
$0.015 |
fallen by
58.33%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- CF33 patent granted in India, further strengthening global intellectual property protection
- Patent provides method of composition and method of use protection until 2037
- The term of this patent is 20 years from the filing date of 9 August 2017
- This patent adds to patent protection in the United States and Japan
- CF33 is a chimeric vaccinia poxvirus developed by Professor Yuman Fong
- Oncolytic viruses selectively target and destroy cancer cells while stimulating the immune system
- Imugene is committed to advancing its oncolytic virotherapy pipeline
- The grant of this patent is a significant step in expanding global protection for CF33
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ARN Media Limited (A1N) ORDINARY FULLY PAID |
Communication Services |
$160 |
Corporate Governance Statement
|
27 Feb 2025 8:58AM |
$0.620 |
$0.510 |
fallen by
17.74%
|
|
| ARN Media Limited (A1N) ORDINARY FULLY PAID |
Communication Services |
$160 |
Appendix 4G Corporate Governance
|
27 Feb 2025 8:58AM |
$0.620 |
$0.510 |
fallen by
17.74%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,382 |
App 3Y Change in Director Interests - C Behrenbruch
|
27 Feb 2025 8:58AM |
$31.000 |
$24.780 |
fallen by
20.06%
|
|
| Beston Global Food Company Limited (BFC) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Trading Update - Appointment of liquidators
|
27 Feb 2025 8:58AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
| Cochlear Limited (COH) ORDINARY FULLY PAID |
Health Care |
$17,844 |
Update - Notification of buy-back - COH
|
27 Feb 2025 8:57AM |
$265.510 |
$272.850 |
risen by
2.76%
|
|
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,074 |
Operating and Financial Review - 31 December 2024
|
27 Feb 2025 8:57AM |
$23.330 |
$18.100 |
fallen by
22.42%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- 1H25 UPAT increased by 2% from 1H24 to $100.5 million.
- NPAT decreased to $12.0 million due to higher significant items.
- Asset Management and Wealth Management segments showed strong growth.
- Strategic review concluded retaining Corporate Trust while pursuing a sale of Wealth Management.
- Ongoing initiatives include business separation and a new operating model.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,074 |
Half Yearly Report and Accounts
|
27 Feb 2025 8:56AM |
$23.330 |
$18.100 |
fallen by
22.42%
|
|
| Infratil Limited (IFT) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Financials |
$9,290 |
Ongoing Disclosure Notice - J Boyes
|
27 Feb 2025 8:56AM |
$9.460 |
$9.520 |
risen by
0.63%
|
|
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,074 |
1H25 Results Presentation
|
27 Feb 2025 8:55AM |
$23.330 |
$18.100 |
fallen by
22.42%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased to $686.2 million in 1H25.
- Underlying profit after tax was $100.5 million.
- Corporate Trust and Wealth Management sectors showed strong growth.
- Net outflows were noted despite overall revenue growth.
- Simplification Program expanded to target $70-80 million in savings by FY27.
- Debt reduction target set at $750-$770 million by June 2025.
- New Asset Management strategy focused on operational efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,074 |
1H25 ASX Announcement
|
27 Feb 2025 8:54AM |
$23.330 |
$18.100 |
fallen by
22.42%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- 1H25 UPAT of A$100.5 million, up 2% on 1H24
- Asset Management UPBT of A$102.6 million, up 7% on 1H24
- Wealth Management UPBT of A$29.2 million, up 12% on 1H24
- Corporate Trust UPBT of A$44.0 million, up 8% on 1H24
- 1H25 NPAT of A$12.0 million compared to A$34.5 million in 1H24
- Assets under Management (AUM) of A$230.2 billion, up 8% on 1H24
- Corporate Trust's Funds Under Administration (FUA) was A$1.25 trillion up 4% on 1H24
- Wealth Management's FUA was A$20.6 billion up 8% on 1H24
- 1H25 total expense growth of 4%, delivered in-line with guidance
- Statutory results impacted by an impairment of A$25.5 million in Asset Management
- An interim dividend of A$0.61 per share declared, unfranked
- FY25 total expense growth guidance of 4% driven by Corporate Trust and Wealth Management
- Uplifted simplification program to deliver annualised cost reductions of A$70 million - A$80 million by FY27
- Progressing with the separation and proposed sale of Wealth Management following termination of the Scheme with KKR
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,074 |
Dividend/Distribution - PPT
|
27 Feb 2025 8:53AM |
$23.330 |
$18.100 |
fallen by
22.42%
|
|
| City Chic Collective Limited (CCX) ORDINARY FULLY PAID |
Consumer Discretionary |
$29 |
Half Year Results Investor Presentation
|
27 Feb 2025 8:53AM |
$0.135 |
$0.075 |
fallen by
44.44%
|
|
CCX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue growth outlined in the presentation.
- Operational efficiencies highlighted across various sectors.
- Continued focus on sustainability practices.
- Engagement with the community emphasized.
- Strategic initiatives aimed at long-term objectives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ARN Media Limited (A1N) ORDINARY FULLY PAID |
Communication Services |
$160 |
Dividend/Distribution - A1N
|
27 Feb 2025 8:53AM |
$0.620 |
$0.510 |
fallen by
17.74%
|
|
| City Chic Collective Limited (CCX) ORDINARY FULLY PAID |
Consumer Discretionary |
$29 |
Half Year Results Announcement
|
27 Feb 2025 8:53AM |
$0.135 |
$0.075 |
fallen by
44.44%
|
|
CCX - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales revenue for 1H FY25 was down 3.6% to $69.5 million.
- Underlying EBITDA improved to $3.5 million from a loss of $5.2 million.
- ANZ revenue increased by 2.8% to $55.3 million with comparable store sales growing by 7.5%.
- Americas revenue decreased by 22.5% to $14.2 million.
- Trading revenue in the first eight weeks of 2H FY25 was up 25% on the prior corresponding period.
- The company is targeting revenue of $137 million to $147 million and EBITDA of $8 million to $12 million for FY25.
- The US market remains volatile, impacting trading margins.
- The group ended the period with a net cash position of $12 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,382 |
Completion of Sale of Shares by Telix CEO
|
27 Feb 2025 8:53AM |
$31.000 |
$24.780 |
fallen by
20.06%
|
|
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,074 |
Appendix 4D
|
27 Feb 2025 8:52AM |
$23.330 |
$18.100 |
fallen by
22.42%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities was $687.7 million, a 3% increase.
- Net profit after tax was $12.0 million, a 65% decrease.
- Underlying net profit after tax was $100.5 million, a 2% increase.
- Interim dividend declared at 61 cents per share.
- Ex-dividend date set for 13 March 2025.
- Record date set for 14 March 2025.
- Payment date for the dividend is 4 April 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
